Drug Used To Protect Bone May Extend Survival In Older Breast Cancer Patients

[News]

The AZURE trial, led by Professor Robert Coleman from the University of Sheffield, has revealed that the bisphosphonate drug zoledronic acid boosts disease-free survival in postmenopausal breast cancer patients but may have an adverse effect on younger women...

More... (http://www.medicalnewstoday.com/releases/235067.php)